Clin Osteol 2026; 31(1): 12-15 | DOI: 10.36290/clo.2026.002

Bone mestastases - a comprehensive overviewMain theme

Martin Marhefka, Aviv Philip Goncharov, Elad Ben Aharon Farzalla, Martina Spisarová, Bohuslav Melichar
Onkologická klinika, Fakultní nemocnice Olomouc

Bone is one of the organs most commonly affected in patients with cancer. The skeletal involvement can be primary or secondary (metastatic), with bone metastases present in up to 70-80 % of all malignancies. In approximately 80 % of patients, bone metastases are caused by four primary tumours: breast, lung, renal and prostatic carcinoma. That is due to both the high incidence and the preference of these tumours to invade into the skeleton. The diagnosis of bone metastases is based on the clinical presentation, laboratory parameters, and confirmatory imaging methods. Subsequent therapy which includes chemotherapy, immunotherapy, hormone therapy, supportive care, radiotherapy and possibly surgical or neurosurgical intervention, depends on tumor factors as well as the overall condition, prognosis, and compliance of the individual patient. This article provides a comprehensive overview of the current knowledge on the diagnosis, treatment, and prevention of bone metastases.

Keywords: bone metastases diagnosis, premetastatic niche, radiotherapy, supportive care, treatment.

Accepted: March 25, 2026; Published: March 30, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marhefka M, Goncharov AP, Aharon Farzalla EB, Spisarová M, Melichar B. Bone mestastases - a comprehensive overview. Clinical Osteology. 2026;31(1):12-15. doi: 10.36290/clo.2026.002.
Download citation

References

  1. Pullan JE, Lotfollahzadeh S. Primary Bone Cancer. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2025 (cited 5-2-2026). Available from: https://www.ncbi.nlm.nih.gov/books/NBK560830/.
  2. Novotný J, Vítek P. Léky modifikující kostní metabolismus. In: Novotný J, Vítek P, Kleibl Z, et al., eds. Onkologie v klinické praxi: standardní přístupy v diagnostice a léčbě vybraných zhoubných nádorů. Praha: Grada Publishing; 2024:482.
  3. Adam Z, Krejčí M, Vorlíček J, et al., eds. Obecná onkologie. Praha: Galén; 2011:175.
  4. Ondroušková E, Sommerová L, Hrstka R. Multistep Process of Establishing Carcinoma Metastases. Klin Onkol. 2016;29(Suppl 4):12-17. Available from: http://dx.doi.org/10.14735/amko20164S12. Go to original source...
  5. Křístek J, Pazourek L, Řehák Z. Kostní metastázy: diagnostika a sledování na zobrazovacích metodách, intervenční radiologie. Onkologie. 2019;13(3):115-122. Available from: http://dx.doi.org/10.36290/xon.2019.023. Go to original source...
  6. Wood TJ, Racano A, Yeung H, et al. Surgical Management of Bone Metastases: Quality of Evidence and Systematic Review. Ann Surg Oncol. 2014;21:4081-4089. Available from: https://doi.org/10.1245/s10434-014-4002-1. Go to original source... Go to PubMed...
  7. Hynková L. Paliativní radioterapie a reiradiace. In: Šlampa P, et al. Radiační onkologie v praxi. Brno: Masarykův onkologický ústav; 2023:325.
  8. Slávik M, Hynková L, Burkoň P, et al. Radioterapie v léčbě metastatického postižení páteře. Klin Onkol. 2016;29(Suppl 2):2S95.
  9. Simos D, Addison CL, Kuchuk I, et al. Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. J Clin Med. 2013;2:67-88. Available from: https://doi.org/10.3390/jcm2030067. Go to original source... Go to PubMed...
  10. Menshawy A, Mattar O, Abdulkarim A, et al. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2018;26(4):1029-1038. Available from: https://doi.org/10.1007/s00520-018-4060-1. Go to original source... Go to PubMed...
  11. Zhong L, Chen W, Zheng D, et al. Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis. Front Oncol. 2025;15:1747354. Available from: https://doi.org/10.3389/fonc.2025.1747354. Go to original source... Go to PubMed...
  12. Adams A, Jakob T, Huth A, et al. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2024;7(7):CD013451. Available from: https://doi.org/10.1002/14651858.CD013451.pub2. Go to original source... Go to PubMed...
  13. Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650-1663. Available from: https://doi.org/10.1016/j.annonc.2020. 07. 019. Go to original source...




Clinical Osteology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.